Johnson & Johnson (JNJ) stock — is it a good business?

Johnson & Johnson (JNJ) stock — is it a good business? — InspectStocks

How it makes money

Innovative Medicine64%
MedTech36%

Shares of revenue are estimates for six months ended June 28, 2026, high confidence, not figures from a filing.

Competes with

What it sells6

DARZALEX
A medicine used to treat multiple myeloma, a cancer of plasma cells.
TREMFYA
A medicine for conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
CARVYKTI
A treatment made from a patient’s modified immune cells for multiple myeloma that has returned or has not responded to earlier treatment.

Show 3 more

VARIPULSE
A system that uses pulsed electrical energy to treat atrial fibrillation, a disorder that causes an irregular heartbeat.
Impella
A heart pump used to support blood circulation in certain patients with heart failure or during high-risk heart procedures.
ACUVUE
A brand of contact lenses sold for vision correction.

Who buys it4

Wholesalers, distributors and retailers that buy medicines and medical products for resale.
Hospitals and clinics that buy medicines and devices for patient care and procedures.
Physicians and other healthcare professionals who prescribe medicines or use medical devices in treatment.
Eye-care professionals and retailers that supply contact lenses and other vision products.

What it stands on, and what could break it

What the business leans on

1Some medicines rely on licenses or partnerships with other companies. For example, a subsidiary licenses patent families related to DARZALEX from Genmab, and IMBRUVICA is co-commercialized in the United States with Pharmacyclics, an AbbVie company.
2The company depends on government approvals and ongoing oversight for its medicines and medical devices, including rules on safety, manufacturing, labeling and sales.
3Sales depend partly on health insurers and government programs deciding whether to cover products and how much they will reimburse; U.S. and other governments can also change medicine-pricing rules.
4The company uses third parties to make or supply some products and relies on complex international manufacturing and distribution chains.

What could go wrong

1Generic and biosimilar competition can reduce sales of medicines when alternatives enter the market. The latest quarterly report describes continuing sales declines for STELARA and says biosimilar competition is also affecting other medicines.
2Government pricing rules, coverage decisions and reimbursement changes can affect what the company receives for medicines and medical devices. The company identifies U.S. drug-pricing measures and tighter regulation across markets as concerns.
3Lawsuits and product-safety claims can lead to substantial costs and affect sales or reputation. The latest quarterly report recorded charges related to talc litigation.

Full financial statements →

About Johnson & Johnson

Johnson & Johnson develops, makes and sells prescription medicines and medical devices around the world. Its two businesses are Innovative Medicine, which sells medicines for conditions including cancer and immune disorders, and MedTech, which sells products used in heart procedures, surgery, orthopaedics and vision care.

Head office: New Brunswick, New Jersey
Founded: 1887 (founding year, high confidence)
Employees: 140,800 (December 28, 2025, high confidence)
Listed on: New York Stock Exchange
Financial year ends: Last Sunday in December

Built from Johnson & Johnson’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Keep exploring

The themes Johnson & Johnson is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The themes it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises